Agenus Inc. (AGEN) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS
Agenus Inc. (NASDAQ:AGEN) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($0.36) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.01, reports. The business had revenue of $3.40 million during the quarter, compared to the consensus estimate of $5.91 million. The firm’s revenue for the quarter was down 24.4% on a year-over-year basis.
Shares of Agenus (NASDAQ:AGEN) opened at $3.50 on Wednesday. The company has a debt-to-equity ratio of -7.93, a current ratio of 3.36 and a quick ratio of 3.36. Agenus has a one year low of $3.20 and a one year high of $5.91.
In related news, CEO Garo H. Armen purchased 100,000 shares of the firm’s stock in a transaction dated Monday, October 30th. The stock was bought at an average price of $3.55 per share, for a total transaction of $355,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 7.90% of the company’s stock.
AGEN has been the subject of several analyst reports. Zacks Investment Research upgraded shares of Agenus from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a research note on Wednesday, October 25th. BidaskClub upgraded shares of Agenus from a “hold” rating to a “buy” rating in a research note on Monday, July 24th. Jefferies Group LLC reiterated a “buy” rating and issued a $7.00 price objective on shares of Agenus in a research note on Friday, August 4th. Finally, ValuEngine upgraded shares of Agenus from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $5.81.
COPYRIGHT VIOLATION NOTICE: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/11/08/agenus-inc-agen-issues-quarterly-earnings-results-beats-estimates-by-0-01-eps.html.
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Stock Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related stocks with our FREE daily email newsletter.